Connect Biopharma IPO Raises $220M
March 18, 2021 – Connect Biopharma Holdings Limited announced its initial public offering of 11,250,000 American Depositary Shares (“ADSs”), representing 11,250,000 ordinary shares of the Company, at a public offering price of US$17.00 per ADS. FLG partner Eric Hall assisted. Company press release.
Read MoreAngion Biomedica Corp. IPO Raises $117M with Concurrent Private Placement
February 9, 2021 – UNIONDALE, N.Y., (GLOBE NEWSWIRE) — Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced the closing of $117 million in gross proceeds from its…Read More
Read MoreAngion Biomedica Enters into a Strategic Partnership with Vifor Pharma
November 9, 2020 – BusinessWire – FLG Partner client, Angion Biomedica and Vifor Pharma have signed a license agreement for ANG-3777 in nephrology indications. Through this strategic partnership, Vifor Pharma acquires a worldwide license, excluding Greater China, to late-stage product ANG-3777. ANG-3777 is a first in class small-molecule hepatocyte growth…Read More
Read MoreHuman API Closes $20M Series C
October 27, 2020 – Human API, a San Mateo, California-based company developing an AI pipeline that structures health data into a standardized format, this week raised over $20 million. A spokesperson for the startup says the capital will be used to scale new products and services that support product design,…Read More
Read MoreLark Closes $55M Series C Followed by $15M in Debt Facilities
MOUNTAIN VIEW, Calif., Oct. 8, 2020 /PRNewswire/ — Lark Health today announced it has closed a $55 million Series C funding round led by King River Capital, as well as a $15 million venture debt credit facility with Trinity Capital and Bridge Bank. The round also includes new investors Franklin Templeton, SteelSky Ventures, and Olive Tree Capital; and…Read More
Read More